The Journal of Liquid Biopsy
Publisher: Elsevier · ISSN 2950-1954 · 52 articles
- Cancer in a Drop: Liquid biopsy insights from AACR 2026
- Longitudinal methylated ctDNA increases predict immunotherapy progression across solid tumors
- Sex hormone balance and PSA-derived biomarkers in cancer-free African migrant men in Italy: Implications for prostate cancer early detection
- A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients
- Associations between early changes in circulating tumor DNA (ctDNA) and outcomes across randomized trials: Insights from the ctMoniTR project
- Early tumor-informed circulating tumor DNA (ctDNA) dynamics correlate with response to first-line advanced NSCLC treated with pembrolizumab ± chemotherapy
- A serum-clinical composite model for prostate cancer diagnosis: multicenter validation and CRISPR/Cas13a-based detection
- Circulating tumor cells predict early skeletal-related events in patients with bone metastases from breast cancer
- A novel imaging-based approach for large extracellular vesicle detection and prognostic stratification in metastatic breast cancer
- Liquid biopsy in oncology practice: A global survey by the Young Committee of the International Society of Liquid Biopsy (ISLB)
- Clinico-genomic risk stratification for biomarker-enriched trial design in poor-prognosis metastatic castrate-resistant prostate cancer (mCRPC)
- Application of PathoChip to urine-derived nucleic acids for broad microbial profiling in men with suspected prostate cancer: setup of a methodological workflow and pilot feasibility study
- ESR1 and PIK3CA circulating tumor DNA (ctDNA) mutation status as predictive biomarkers beyond variant allele fraction (VAF) in metastatic breast cancer
- Impact of methodological variability on the prognostic performance of circulating tumor DNA in colorectal cancer: A systematic review and meta-analysis
- Molecular sampling limits of ctDNA detection in clinical plasma samples
- Cancer in a drop: Liquid biopsy highlights from the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting
- Multimodal Liquid Biopsy for Prostate Cancer Stratification
- Longitudinal residual disease stratification with PD-L1-expressing circulating tumor cells in breast cancer
- Plasma ctDNA Tumor Fraction as an Independent Prognostic Factor in Metastatic Colorectal Cancer: Differential Prognostic Impact Across Treatment Lines and Irrespective of Hepatic Metastatic Burden
- Molecular Testing of Solid Tumors using Liquid Biopsy: a position paper of Italian Scientific Societies☆
- CellSearch-based isolation of circulating tumor cells from ascitic fluid enables molecular characterization of ovarian cancer
- Circulating immune profiling reveals immune signatures associated with disease stage and outcome in endometrial cancer
- Using cell free DNA (cfDNA) and RNA (cfRNA) in the diagnosis and monitoring of primary and metastatic CNS tumors
- Comparative diagnostic value of a blood-based three-gene DNA methylation assay and a seven-autoantibody panel for differentiating pulmonary nodules
- Minimal residual disease combined with radiological tumor volume as a tool for identification of resected NSCLC patients at high risk of recurrence
- A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring
- Storage-dependent changes in the soluble urinary proteome: a pre-analytical stability study in inflammatory clinical urine samples
- Cerebrospinal fluid circulating tumor DNA profiling in central nervous system metastases from solid tumors: A prospective multicentre translational analysis of the BrainStorm (OncoDistinct-006) study
- Beyond variant detection: Mismatch repair gene alterations in plasma cell-free DNA from 1,226 glioma samples, and plasma-confirmed functional deficiency in an unbiopsied pontine glioma
- A cfDNA fragmentomics-based machine learning model for predicting treatment response and recurrence in locally advanced rectal cancer after neoadjuvant chemoradiotherapy